Polymorphisms associated with anti‐TNF drugs response in patients with psoriasis and psoriatic arthritis

Ovejero‐Benito, María C.; Muñoz‐Aceituno, Ester; Reolid, Alejandra; Fisas, L.H.; Llamas‐Velasco, M.; Prieto-Pérez, Rocío; Abad‐Santos, Francisco; Daudén, E.

doi:10.1111/jdv.15431

Cited by 18 publications

(20 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…examined 10 polymorphisms located in genes related to TNF in 20 PsA patients treated with TNFi therapy. 33 rs6920220 and rs610604 mapping the TNFAIP3 gene showed a significant association with an improvement EuroQol score after 3 months of treatment. Fabris et al .…”

Section: Resultsmentioning

confidence: 89%

Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review

Magee

Jethwa

FitzGerald

et al. 2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Aims: The ability to predict response to treatment remains a key unmet need in psoriatic disease. We conducted a systematic review of studies relating to biomarkers associated with response to treatment in either psoriasis vulgaris (PsV) or psoriatic arthritis (PsA). Methods: A search was conducted in PubMed, Embase and the Cochrane library from their inception to 2 September 2020, and conference proceedings from four major rheumatology conferences. Original research articles studying pre-treatment biomarker levels associated with subsequent response to pharmacologic treatment in either PsV or PsA were included. Results: A total of 765 articles were retrieved and after review, 44 articles (22 relating to PsV and 22 to PsA) met the systematic review’s eligibility criteria. One study examined the response to methotrexate, one the response to tofacitinib and all the other studies to biologic disease-modifying antirheumatic drugs (DMARDs). Whilst several studies examined the HLA-C*06 allele in PsV, the results were conflicting. Interleukin (IL)-12 serum levels and polymorphisms in the IL-12B gene show promise as biomarkers of treatment response in PsV. Most, but not all, studies found that higher baseline levels of C-reactive protein (CRP) were associated with a better clinical response to treatment in patients with PsA. Conclusion: Several studies have identified biomarkers associated with subsequent response to treatment in psoriatic disease. However, due to the different types of biomarkers, treatments and outcome measures used, firm conclusions cannot be drawn. Further validation is needed before any of these biomarkers translate to clinical practice.

show abstract

Section: Resultsmentioning

confidence: 89%

Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review

Magee

Jethwa

FitzGerald

et al. 2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…Several of them investigated genes involved in SpA pathogenetic mechanisms, in particular TNFα, TNFα receptors, and several interleukins (IL) both with pro inflammatory (e.g., IL-6) and anti-inflammatory (e.g., IL-10) effects. Polymorphisms of the TNF receptor superfamily 1 A and 1B (TNFRSF1A/1B) genes were those that most frequently were able to predict response (TNFRSF1A rs767455 genotype AA, TNFRSF1A rs1800693 genotype GG, TNFRSF1B rs1061622 genotype TT and GG) according to various criteria such as BASDAI 50, EULAR response, or ASAS 20, ASAS 40 (Morales-Lara et al, 2010;Julià et al, 2014;Ovejero-Benito et al, 2019). Notably, Schiotis et al, who also investigated the TNFRSF1B polymorphism rs1061622, found that the GG genotype was associated with non-response, thus reaching opposite conclusion compared to the previously mentioned studies despite a fair numerosity and correcting for other polymorphisms (Schiotis et al, 2014).…”

Section: Genes Involved In Spa Pathogenesismentioning

confidence: 99%

The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

Objective: Spondyloarthritis (SpA) are a group of diseases with a high heritability, whose pathogenesis is strongly determined by an interplay between genetic and environmental factor. Therefore, the aim of our study was to determine whether genetic variants could also influence response to therapy in SpA.Methods: A systematic literature review (SLR) was conducted in PubMed and Web of Science core collection, without publication-year restrictions (Last search 8th April 2021). The search strategy was formulated according to the PEO format (Population, Exposure, Outcome) for observational studies. The population was adult (≥18 years) patients with SpA. The exposure was inheritable genetic variations of any gene involved in the disease pathogenesis/drug metabolism. The outcome was response to the drug, both as dichotomous (response yes/no) and as continuous outcomes. Exclusion criteria were: (1) languages other than English, (2) case series, case reports, editorials, and reviews, (3) studies reporting genetic contribution to drug response only limited to extra-musculoskeletal features of SpA, (4) epigenetic modifications. Quality of the included study was independently assessed by two authors.Results: After deduplication, 393 references were screened by two authors, which led to the final inclusion of 26 articles, pertinent with the research question, that were considered for qualitative synthesis. Among these, 10 cohort, one cross-sectional, and five case-control studies were considered of at least good quality according to Newcastle-Ottawa Scale (NOS). In studies about TNF-blockers therapy: (1) polymorphisms of the TNF receptor superfamily 1A/1B (TNFRSF1A/1B) genes were most frequently able to predict response, (2) −238 and −308 polymorphisms of TNFα gene were studied with conflicting results, (3) TNFα polymorphism rs1799724, rs1799964, −857, −1,013, +489 predicted drug response in non-adjusted analysis, (4) PDE3A rs3794271 had a linear relationship with DAS28 reduction after anti-TNFα therapy. DHFR polymorphism +35,289 was able to predict response to methotrexate.Conclusions: Our SLR highlighted the existence of a genetic component in determining drug response. However, further studies are warranted to better define quantify it.

show abstract

“…In PsA, polymorphisms in TNFAIP3 have been correlated with an improvement in quality of life (as measured by European Quality of life Visual Analogue Scale (EQ-VAS)) after TNF inhibitor treatment [107]. Other SNPs associated with TNF have included the −308A allele, which predicts TNF inhibitor survival [108], and the +489 A allele, associated with responsiveness to etanercept [109].…”

Section: Predicting Treatment Responsementioning

confidence: 99%

Applying precision medicine to unmet clinical needs in psoriatic disease

2020

View full text Add to dashboard Cite

Psoriatic disease is a heterogeneous condition that can affect peripheral and axial joints (arthritis), entheses, skin (psoriasis) and other structures. Over the past decade, considerable advances have been made both in our understanding of the pathogenesis of psoriatic disease (PsD) and in the treatment of its diverse manifestations. However, several major areas of continued unmet need in the care of patients with PsD have been identified. One of these areas is the prediction of poor outcome, notably radiographic outcome in patients with psoriatic arthritis, so that stratified medicine approaches can be taken; another is predicting response to the numerous current and emerging therapies for PsD, so that precision medicine can be applied to rapidly improve clinical outcome and reduce the risk of toxicity. In order to address these needs, novel approaches, including imaging, tissue analysis and the application of proteogenomic technologies, are proposed as methodological solutions that will assist the dissection of the critical immune-metabolic pathways in this complex disease. Learning from advances made in other inflammatory diseases, it is time to address these unmet needs in a multi-centre partnership aimed at improving short-term and long-term outcomes for patients with PsD.

show abstract

Polymorphisms associated with anti‐TNF drugs response in patients with psoriasis and psoriatic arthritis

Cited by 18 publications

References 10 publications

Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review

Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review

The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review

Applying precision medicine to unmet clinical needs in psoriatic disease

Contact Info

Product

Resources

About